Search

Your search keyword '"Amitriptyline adverse effects"' showing total 1,132 results

Search Constraints

Start Over You searched for: Descriptor "Amitriptyline adverse effects" Remove constraint Descriptor: "Amitriptyline adverse effects"
1,132 results on '"Amitriptyline adverse effects"'

Search Results

1. Topical amitriptyline in burning mouth syndrome: A retrospective real-world evidence study.

2. [Serotonin syndrome secondary to the association of paroxetine and amitriptyline: a case report].

Catalog

Books, media, physical & digital resources

3. Utilization of Lower-Dose Cyclobenzaprine in the Older Inpatient.

4. Treatment of Brachioradial Pruritus: A Tertiary Center Retrospective Analysis.

5. Pregabalin and amitriptyline as first-line drugs among patients with painful peripheraldiabetic neuropathy: a systematic review and meta-analysis.

6. Amitriptyline induced rosacea-like rash.

7. QTc Shortening on Electrocardiogram With Amitriptyline May Indicate No Effect on Pain Relief in Burning Mouth Syndrome.

8. Adverse drug events associated with nortriptyline compared with paroxetine and alternative medications in an older adult population: a retrospective cohort study in Southern California.

9. [A naturalistic study on the effects of antidepressants (e. g. SSRI) and acetyl salicylic acid (ASA) on the self-rated perception of the psychotherapeutic process of inpatient psychosomatic treatment and its results: Could ASA be beneficial?]

10. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.

11. Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.

12. An investigation of the potential effects of amitriptyline on polycystic ovary syndrome induced by estradiol valerate.

13. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline.

14. Off-label low dose amitriptyline for insomnia disorder: Patient-reported outcomes.

16. Therapeutic potential of amitriptyline for paraquat-induced pulmonary fibrosis: Involvement of caveolin-1-mediated anti-epithelial-mesenchymal transition and inhibition of apoptosis.

17. Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors.

18. Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT.

19. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".

20. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.

21. Risk of maculopathy with pentosan polysulfate sodium use.

22. Efficacy of amitriptyline in pediatric functional abdominal pain disorders: A randomized placebo-controlled trial.

23. Venlafaxine can reduce the migraine attacks as well as amitriptyline: A noninferiority randomized trial.

24. Antioxidants Supplementation in Acute Amitriptyline Abuse for Pain.

25. Amitriptyline blocks innate immune responses mediated by toll-like receptor 4 and IL-1 receptor: Preclinical and clinical evidence in osteoarthritis and gout.

26. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial.

27. Analgesic Effects of Topical Amitriptyline in Patients With Chemotherapy-Induced Peripheral Neuropathy: Mechanistic Insights From Studies in Mice.

28. Amitriptyline-Induced Multifocal Oral Mucosal Dyspigmentation-Bridging Pharmacopsychodermatology in Skin of Color.

30. Antidepressants for functional abdominal pain disorders in children and adolescents.

31. Fetal teratogenicity in a rhesus macaque (Macaca mulatta): Association with the chronic maternal treatment of amitriptyline.

33. Non-lethal Amitriptyline Overdosage Mimicking Brain Death.

34. An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine.

35. Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews.

36. A stereological study of the effects of antidepressants on postmenopausal rat kidney.

37. The Link Between Amitriptyline and Movement Disorders: Clinical Profile and Outcome.

38. Adverse drug reactions associated with amitriptyline - protocol for a systematic multiple-indication review and meta-analysis.

39. The Brugada pattern in a patient treated with amitriptyline.

40. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.

41. A Rare Case of Lichen Planus-Like Atopic Dermatitis Involving the Hands.

42. Nortriptyline serum concentration as a predictor for cardiac risk in amitriptyline-treated patients.

43. Transfer of Cyclobenzaprine into Human Milk and Subsequent Infant Exposure.

44. Autonomic Dysreflexia as a Potential Adverse Effect of Duloxetine and Amitriptyline Combination Therapy: A Case Report.

45. QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients.

46. Drug-induced Creutzfeldt-Jakob disease-like syndrome: early CSF analysis as useful tool for differential diagnosis.

47. An Evaluation of Efficacy and Safety of Commonly Prescribed Drugs and Effect of These Drugs on Quality of Sleep in Patients Suffering From Zoster-Associated Pain.

48. Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial.

49. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.

50. An increase in salivary flow with amitriptyline may indicate treatment resistance in burning mouth syndrome.